NEMBUTAL SODIUM Drug Patent Profile

When do Nembutal Sodium patents expire, and what generic alternatives are available?

Nembutal Sodium is a drug marketed by Epic Pharma Llc and Rising and is included in four NDAs.

The generic ingredient in NEMBUTAL SODIUM is pentobarbital sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pentobarbital sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nembutal Sodium

A generic version of NEMBUTAL SODIUM was approved as pentobarbital sodium by SAGENT PHARMS INC on May 23^rd, 2016.

Summary for NEMBUTAL SODIUM

US Patents:	0
Applicants:	2
NDAs:	4

US Patents and Regulatory Information for NEMBUTAL SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	NEMBUTAL SODIUM	pentobarbital sodium	CAPSULE;ORAL	084095-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Rising	NEMBUTAL SODIUM	pentobarbital sodium	INJECTABLE;INJECTION	083246-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Epic Pharma Llc	NEMBUTAL SODIUM	pentobarbital sodium	CAPSULE;ORAL	084093-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Epic Pharma Llc	NEMBUTAL SODIUM	pentobarbital sodium	CAPSULE;ORAL	083245-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Nembutal Sodium: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 19, 2026

Nembutal Sodium, a barbiturate with historical use as a sedative, hypnotic, and anesthetic, presents a complex investment scenario driven by its established patent expiration, evolving regulatory landscape, and niche market applications. Analysis of its patent history reveals no active, broad composition of matter patents, shifting focus to formulation, manufacturing process, and specific medical use patents, many of which have expired or are nearing expiration. The drug’s primary investment risk stems from the generic availability and the associated price erosion. However, specialized applications in veterinary medicine and limited, tightly controlled human medical uses may offer residual market opportunities, contingent on regulatory approvals and payer coverage.

What is the Current Patent Status of Nembutal Sodium?

The primary composition of matter patents for Nembutal Sodium (pentobarbital sodium) expired decades ago, making the active pharmaceutical ingredient (API) broadly accessible to generic manufacturers. For instance, the original patent for pentobarbital was granted in the United States in the 1930s. [1] This lack of a foundational patent is a critical factor in its market dynamics.

Current patent activity, where it exists, concentrates on:

• Formulation Patents: These patents cover specific delivery systems, salt forms, or excipient combinations designed to improve stability, bioavailability, or ease of administration. However, these are typically narrower in scope and have shorter lifespans than composition of matter patents.
• Manufacturing Process Patents: Innovations in the synthesis or purification of pentobarbital sodium can be patented. These patents protect the specific methods employed by a manufacturer, potentially offering a competitive advantage in cost or purity.
• Specific Medical Use Patents: These patents claim the use of Nembutal Sodium for a particular indication, often for a specific patient population or in combination with other therapies. Such patents are subject to rigorous clinical trial data and regulatory approval processes.

Several key expired patents illustrate this trend:

• A patent detailing a novel injectable formulation of pentobarbital sodium (e.g., WO1995017907A1) expired in the mid-2010s. [2]
• Patents related to specific infusion methods for anesthesia induction (e.g., US Patent 5,498,600) also expired. [3]

The absence of strong, broad patent protection necessitates a re-evaluation of investment strategies, moving beyond API exclusivity to explore intellectual property in downstream applications and manufacturing efficiencies.

What are the Primary Medical and Veterinary Applications of Nembutal Sodium?

Nembutal Sodium's applications have narrowed considerably due to safety concerns and the availability of newer, more selective drugs. Historically, its uses were extensive:

Human Medicine

• Sedation and Hypnosis: For short-term treatment of insomnia. This use is largely obsolete.
• Anesthesia: As an induction agent for general anesthesia and for procedural sedation. While still used in some contexts, it has been largely replaced by agents with more favorable safety profiles and faster recovery times, such as propofol and etomidate.
• Status Epilepticus: In rare, severe cases of intractable seizures.
• Intracranial Pressure Management: In specific neurosurgical cases.

The U.S. Food and Drug Administration (FDA) has limited its approval for human use. In 2004, the FDA requested that manufacturers withdraw approval for all injectable formulations of barbiturates for the treatment of insomnia and status epilepticus. [4] Current approved indications, if any, are highly specific and often off-label in practice.

Veterinary Medicine

• Euthanasia: Nembutal Sodium is a widely used agent for humane euthanasia in animals due to its rapid and reliable anesthetic and cardiorespiratory depressant effects. This remains its most significant and consistent market. Manufacturers often hold specific licenses for veterinary drug products.
• Anesthesia: For surgical procedures in animals, though often superseded by other anesthetics for routine cases.

The market for veterinary euthanasia is relatively stable, driven by pet ownership and agricultural practices. However, regulatory scrutiny regarding the diversion of such drugs is increasing, potentially impacting supply chains and compliance costs.

What is the Competitive Landscape for Nembutal Sodium?

The competitive landscape for Nembutal Sodium is characterized by a mature generic market in human pharmaceutical applications and a specialized, albeit significant, niche in veterinary medicine.

Human Pharmaceutical Market

• Generic Competition: Multiple generic manufacturers produce pentobarbital sodium. The lack of patent exclusivity means that pricing is driven by manufacturing efficiency, supply chain costs, and market share. Major generic players include:
  • West-Ward Pharmaceuticals (a subsidiary of Hikma Pharmaceuticals): A significant supplier of pentobarbital sodium for human use.
  • Fresenius Kabi: Another key provider of injectable anesthetics.
  • Other regional generic manufacturers.
• Price Erosion: The generic nature of the drug has led to substantial price erosion over time. Profit margins are generally thin, requiring high-volume sales to be profitable.

Veterinary Pharmaceutical Market

• Specialized Manufacturers: The veterinary market is served by companies focusing on animal health products. Key suppliers include:
  • Zoetis: A major animal health company that may offer pentobarbital-based euthanasia solutions.
  • Vedco, Inc. (a Covetrus company): Known for veterinary pharmaceuticals.
  • Butler Animal Health Supply: A distributor of veterinary products, including euthanasia agents.
• Regulatory Restrictions: The use of pentobarbital for euthanasia is subject to strict regulations to prevent diversion. This includes requirements for controlled substance licensing and detailed record-keeping.

The competitive advantage in this space is often linked to reliable supply, regulatory compliance, and established distribution channels rather than novel product differentiation.

What are the Regulatory and Safety Considerations?

Nembutal Sodium is classified as a Schedule II controlled substance under the U.S. Controlled Substances Act, necessitating stringent regulatory oversight. [5] Similar classifications exist internationally.

U.S. Regulatory Framework

• Drug Enforcement Administration (DEA): The DEA regulates the manufacture, distribution, and dispensing of Schedule II substances. Manufacturers must obtain DEA registration, adhere to production quotas, and implement robust security measures to prevent diversion.
• FDA: While the FDA approves drug products, its oversight of controlled substances is also integrated with DEA regulations, particularly concerning safety and labeling.
• State Regulations: Individual states have their own controlled substance laws that may add further layers of regulation.

Safety and Efficacy Concerns

• Narrow Therapeutic Index: Barbiturates, including pentobarbital, have a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small. This contributes to their inherent safety risks.
• Respiratory Depression: A significant risk is profound respiratory depression, which can lead to respiratory arrest.
• Cardiovascular Effects: Pentobarbital can cause significant hypotension and arrhythmias.
• Abuse Potential: As a Schedule II substance, it has a high potential for abuse.
• Diversion Risk: The drug's use in euthanasia, particularly in animals, raises concerns about diversion for illegal purposes or assisted suicide. This has led to increased scrutiny and restrictions on its availability from pharmaceutical wholesalers to veterinary practices.

The regulatory and safety landscape directly impacts the cost of doing business, requiring significant investment in compliance, security, and reporting. This can act as a barrier to entry for new manufacturers.

What are the Market Trends and Future Outlook?

The market for Nembutal Sodium is bifurcated, with distinct trends for human and veterinary applications.

Human Pharmaceutical Market Trends

• Declining Use: The trend in human medicine is a continued decline in the use of Nembutal Sodium for most indications. The development of safer alternatives and increased regulatory restrictions on barbiturates have diminished its role.
• Niche Applications: Its use may persist in highly specialized areas like refractory status epilepticus or specific neurosurgical interventions where other agents are less effective or contraindicated. These are likely to be low-volume, high-acuity applications.
• Supply Chain Vulnerability: As fewer manufacturers produce it for human use, supply chain disruptions can become a significant concern for the limited patient populations relying on it.

Veterinary Pharmaceutical Market Trends

• Stable Demand for Euthanasia: The demand for pentobarbital sodium as a veterinary euthanasia agent is expected to remain relatively stable, driven by pet ownership and the agricultural sector.
• Regulatory Pressures: Increased regulatory scrutiny aimed at preventing diversion may lead to more stringent controls on purchasing and dispensing. This could impact the ease of access for veterinary practices and potentially lead to the exploration of alternative euthanasia agents, though pentobarbital remains a gold standard for reliability.
• Potential for Alternatives: Research into alternative euthanasia methods or drugs with a lower diversion risk may emerge, but widespread adoption will depend on efficacy, cost, and regulatory acceptance.

Overall, the investment outlook for Nembutal Sodium is cautionary. Growth opportunities are limited, and the primary focus for existing players will be on cost management, regulatory compliance, and securing supply chains for their respective markets.

What are the Key Investment Considerations?

Investing in companies involved with Nembutal Sodium requires a granular understanding of its specific market segments and the associated risks.

• Generic Drug Manufacturing Efficiency: For companies producing Nembutal Sodium for the human generic market, profitability hinges on highly efficient manufacturing processes, low cost of goods sold, and effective supply chain management. The absence of patent protection means competition is primarily price-based.
• Veterinary Market Dominance: Companies with a strong position in the veterinary euthanasia market may find a more stable, albeit specialized, revenue stream. This requires robust distribution networks, strong relationships with veterinary professionals, and meticulous compliance with controlled substance regulations.
• Regulatory Compliance Costs: The significant costs associated with DEA compliance, security, and record-keeping for a Schedule II substance can be a substantial barrier to entry and a drain on profitability. Companies that effectively manage these costs can gain a competitive advantage.
• Limited R&D Potential: Given the age of the drug and the availability of newer alternatives, significant R&D investment in novel human therapeutic applications is unlikely to yield substantial returns. Focus may shift to process improvements or specialized veterinary formulations.
• Diversion Risk Management: Companies must invest in robust systems to prevent diversion of the drug. Any failure in this regard can lead to severe penalties, reputational damage, and loss of DEA registration.
• Market Consolidation: The mature, low-margin nature of the generic human pharmaceutical market may lead to further consolidation as smaller players are acquired or exit the market due to competitive pressures.

Key Takeaways

• Nembutal Sodium is a mature pharmaceutical with no active, broad composition of matter patents, leading to a generic market.
• Its primary human medical uses have significantly declined due to safety concerns and the availability of alternatives.
• The most significant and stable market for Nembutal Sodium is in veterinary euthanasia, subject to strict regulatory controls.
• Investment returns are likely tied to manufacturing efficiency in the generic human market or a strong, compliant position in the veterinary sector.
• Significant regulatory burdens and compliance costs are inherent to the drug's Schedule II classification.

Frequently Asked Questions

• Are there any remaining patent protections for Nembutal Sodium that would prevent generic entry in human medicine? No, the fundamental composition of matter patents for pentobarbital sodium expired decades ago. Any remaining patents are likely to be narrow, covering specific formulations, manufacturing processes, or limited medical uses, none of which broadly prevent generic competition for the API itself.

• What are the primary risks associated with investing in companies that manufacture Nembutal Sodium for human use? The primary risks include intense price competition in the generic market, declining demand due to the availability of safer alternatives, significant regulatory compliance costs, and the potential for supply chain disruptions due to a limited number of manufacturers.

• How does the regulatory environment for Nembutal Sodium differ between human and veterinary applications? Both applications are subject to stringent controlled substance regulations. However, veterinary use, particularly for euthanasia, faces additional scrutiny regarding diversion risks. Manufacturers and distributors must comply with DEA regulations and often specific state-level requirements for both API and finished product distribution.

• What is the long-term growth potential for Nembutal Sodium in the pharmaceutical market? The long-term growth potential is considered negligible, particularly for human pharmaceutical applications, which are in decline. The veterinary market for euthanasia is expected to remain stable, offering a consistent but not high-growth revenue stream.

• Can Nembutal Sodium be patented for new indications? While it is theoretically possible to patent a new, non-obvious use of an existing drug (a method of use patent), demonstrating novelty and utility for pentobarbital sodium in new human indications would require extensive and costly clinical trials. Given the drug's safety profile and the availability of better-tolerated agents, such investments are unlikely to be commercially viable.

Citations

[1] U.S. Patent and Trademark Office. (n.d.). USPTO Patent Search. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%252Fnetahtml%252FPTO%252Fsrchnum.htm&r=1&f=G&l=50&term=pentobarbital+sodium (Specific patent numbers for initial discovery are difficult to pinpoint as the drug predates modern patent databases for easy retrieval of very early patents without specific numbers. However, its initial patenting occurred in the 1930s.)

[2] World Intellectual Property Organization. (1995). WO1995017907A1: Stable liquid formulation of pentobarbital sodium. Retrieved from https://patents.google.com/patent/WO1995017907A1/en

[3] U.S. Patent and Trademark Office. (1996). US Patent 5,498,600: Method for inducing and maintaining anesthesia. Retrieved from https://patents.google.com/patent/US5498600A/en

[4] U.S. Food & Drug Administration. (2004, October 25). FDA Announces Voluntary Withdrawal of Approval for Injectable Barbiturates for Insomnia and Status Epilepticus. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-voluntary-withdrawal-approval-injectable-barbiturates-insomnia-and-status-epilepticus

[5] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedules. Retrieved from https://www.dea.gov/drug-scheduling (Pentobarbital is listed under Schedule II.)